Johnson & Johnson Reports Positive CAPLYTA Phase 3 Data
Titusville, New Jersey, U.S., September 21, 2026 Johnson & Johnson has announced positive topline results from a pivotal Phase...
Mental Health
Advertisement
Teva Study Examines Treatment Selection in Schizophrenia
Tel Aviv, Israel, September 18, 2026 Teva Pharmaceuticals has announced new findings from a study examining the factors that...
Teva Highlights New UZEDY Data in Schizophrenia Care
Parsippany, New Jersey, September 21, 2026 Teva Pharmaceuticals has announced new real-world data for UZEDY® (risperidone) extended-release injectable suspension,...
Antengene Advances ATG-022 Into Phase III Gastric Cancer Study
Shanghai and Hong Kong, PRC, September 21, 2026 Antengene Corporation Limited has announced the dosing of the first patient...
Teva Reports New TEV-749 Olanzapine LAI Clinical Data
Tel Aviv, Israel, September18, 2026 Teva Pharmaceutical Industries Ltd. has announced new post hoc clinical data for TEV-‘749, its...
Advertisements
AbbVie Reports New Real-World VRAYLAR Data in Depression
North Chicago, Illinois, September 18, 2026 AbbVie has announced new real-world data for VRAYLAR® (cariprazine) presented at Psych Congress...
Clearmind Briefs FDA on Psychedelic Therapy and Patient Access
VANCOUVER, Canada — September 17, 2026 Clearmind Medicine announced that its Chief of Global Impact, Mary-Elizabeth Gifford, testified at...
Array Behavioral Care Launches Rapid Care for Urgent Needs
Philadelphia, Pennsylvania, U.S., September 18, 2026 Array Behavioral Care, a provider of virtual behavioral health services, has introduced Array...
Compass Pathways Launches Change the Tune in TRD
LONDON and NEW YORK — September 15, 2026 Compass Pathways plc announced the launch of Change the Tune in...
Compass Pathways Names U.S. Grant Recipients for COMP360 Training
LONDON and NEW YORK — September 10, 2026 Compass Pathways plc announced that five organizations have been awarded grants...
Advertisement
